CA
SOPH icon

CoreCap Advisors’s SOPHiA GENETICS SOPH Stock Holding History

CoreCap Advisors’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83K Buy
+490
New +$2.49K ﹤0.01% 2447

Other funds holding SOPH

BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
BPCE
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.12B AUM 27.39% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

CoreCap Advisors's SOPH Position: Q2 2026 in Review

CoreCap Advisors opened a new position in SOPHiA GENETICS (SOPH) in Q2 2026: 490 shares worth $2.83K. The stake represents ﹤0.01% of the portfolio and ranks #2447 among its holdings.

9 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

  • CoreCap Advisors held 490 shares of SOPHiA GENETICS worth $2.83K as of Q2 2026.
  • SOPHiA GENETICS was a new CoreCap Advisors position in Q2 2026.
  • SOPHiA GENETICS made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2447 holding.
  • 9 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.